Please login to the form below

Not currently logged in
Email:
Password:

Crescendo Biologics appoints Peter Pack as CEO

Launches new strategy in oncology R&D
Crescendo Peter Pack

Crescendo Biologics has appointed Dr Peter Pack as CEO who will help to oversee the company's new strategy.

Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics.

Dr Pack joins with over 23 years of corporate experience in the life science industry. He has also previously served on the board of Signature Diagnostics AG before its sale to Roche in February 2015. 

His appointment is representative of Crescendo expanding its oncology pipeline by targeting a range of cancer indications where humabodies have the potential to deliver high-value treatments to patients where there is an unmet medical need.

He said: “The transition to a product-oriented oncology therapeutics company is a pivotal moment in Crescendo's corporate development. In my view Crescendo's in vivo maturation technology for 100% human VHs with excellent affinities, expression yields and plug and play options is superior to anything that has been done before.

“We plan to advance the development of new and innovative therapeutics compounds in the area of oncology including immune-oncology, the new primary focus of the work at Crescendo. We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a novel alternative to antibody drug conjugates.”

20th October 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics